The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has plunged by -29.85 when compared to previous closing price of 2.01, but the company has seen a -35.32% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-22 that Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is diving on Monday after the biopharmaceutical company announced plans to wind down a clinical trial. A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study.
Is It Worth Investing in Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Right Now?
HEPA has 36-month beta value of 1.64. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HEPA is 5.39M, and currently, short sellers hold a 1.17% ratio of that float. The average trading volume of HEPA on April 23, 2024 was 76.71K shares.
HEPA’s Market Performance
HEPA’s stock has seen a -35.32% decrease for the week, with a -39.22% drop in the past month and a -32.54% fall in the past quarter. The volatility ratio for the week is 13.84%, and the volatility levels for the past 30 days are at 10.80% for Hepion Pharmaceuticals Inc The simple moving average for the last 20 days is -39.29% for HEPA stock, with a simple moving average of -67.30% for the last 200 days.
Analysts’ Opinion of HEPA
Many brokerage firms have already submitted their reports for HEPA stocks, with ROTH Capital repeating the rating for HEPA by listing it as a “Buy.” The predicted price for HEPA in the upcoming period, according to ROTH Capital is $14 based on the research report published on July 20, 2020 of the previous year 2020.
HEPA Trading at -38.92% from the 50-Day Moving Average
After a stumble in the market that brought HEPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.18% of loss for the given period.
Volatility was left at 10.80%, however, over the last 30 days, the volatility rate increased by 13.84%, as shares sank -40.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.69% lower at present.
During the last 5 trading sessions, HEPA fell by -35.32%, which changed the moving average for the period of 200-days by -85.34% in comparison to the 20-day moving average, which settled at $2.28. In addition, Hepion Pharmaceuticals Inc saw -56.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HEPA starting from Wijngaard Peter, who purchase 2,500 shares at the price of $3.05 back on Nov 27 ’23. After this action, Wijngaard Peter now owns 9,501 shares of Hepion Pharmaceuticals Inc, valued at $7,625 using the latest closing price.
Wijngaard Peter, the Director of Hepion Pharmaceuticals Inc, purchase 2,500 shares at $3.09 during a trade that took place back on Nov 24 ’23, which means that Wijngaard Peter is holding 7,001 shares at $7,725 based on the most recent closing price.
Stock Fundamentals for HEPA
The total capital return value is set at -3.78. Equity return is now at value -171.26, with -123.92 for asset returns.
Based on Hepion Pharmaceuticals Inc (HEPA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -195.62. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -10367.63.
Currently, EBITDA for the company is -45.19 million with net debt to EBITDA at 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.31.
Conclusion
To put it simply, Hepion Pharmaceuticals Inc (HEPA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
